Naveed Sheikh, MD
Pulmonary Disease · Lawrenceville, GANPI 1477794873
Payments from drug & device makers
Across 82 payments — averaging $44.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- GSK$301
- Insmed, Inc.$295
- AstraZeneca$267
- Boehringer Ingelheim$207
- Inspire Medical Systems, Inc.$137
- plus $813 from 20 others
What the payments were for
- Food & beverage$2,00655%
- Education$1,62945%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $1,615 |
| GSK | 17 | $301 |
| Insmed, Inc. | 10 | $295 |
| AstraZeneca | 15 | $267 |
| Boehringer Ingelheim | 8 | $207 |
| Inspire Medical Systems, Inc. | 1 | $137 |
| Pulmonx Corporation | 1 | $129 |
| EKOS Corporation | 1 | $108 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Amgen | 4 | $77 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $37 |
| Verona Pharma, Inc. | 2 | $35 |
| Sanofi | 1 | $32 |
| Resmed Corp | 2 | $29 |
| United Therapeutics Corporation | 1 | $25 |
| AbbVie | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $23 |
| Viatris Specialty LLC | 1 | $21 |
| Pfizer | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| Veran Medical Technologies, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,500
- Inspire$137
- Pulmonx Endobronchial Valve EBV$129
- EKOSONIC$108
How this compares
$3,635 in reported general payments places this provider in the 40th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 33 | $425,904 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 279 | $215,668 |
| Breo ElliptaFluticasone/Vilanterol | 141 | $64,244 |
| TezspireTezepelumab-Ekko | 12 | $53,219 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 104 | $51,753 |
| Spiriva RespimatTiotropium Bromide | 34 | $26,093 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $18,487 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 30 | $12,970 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $12,958 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 66 | $12,388 |
| EliquisApixaban | 16 | $12,043 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 413 | $11,305 |
| Wixela InhubFluticasone Propion/Salmeterol | 41 | $6,077 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 20 | $3,499 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $207 | $470,48493 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $301 | $331,665524 claims |
| AstraZenecaTezspire, Bevespi Aerosphere, Breztri Aerosphere, Symbicort | $267 | $82,15676 claims |
| PfizerEliquis | $19 | $12,04316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Lawrenceville
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
- Lawrence McDermottSavannah$963K
- Ngozika OrjiokeEast Point$846K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.